Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ANI Pharmaceuticals, Inc. - Common Stock (NQ:ANIP)

67.19 -1.10 (-1.61%)
Streaming Delayed Price Updated: 11:53 AM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 235,616
Open 66.02
Bid (Size) 66.89 (2)
Ask (Size) 67.49 (3)
Prev. Close 68.29
Today's Range 65.13 - 68.40
52wk Range 52.50 - 70.00
Shares Outstanding 24,422,240
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Russell 2000 Stocks in the Doghouse
Small-cap stocks in the Russell 2000 can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these... 
Via StockStory
Q4 Earnings Roundup: Elanco (NYSE:ELAN) And The Rest Of The Pharmaceuticals Segment
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how pharmaceuticals stocks fared in Q4, starting with Elanco... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property

Performance

YTD
+21.2%
+21.2%
1 Month
+13.6%
+13.6%
3 Month
+21.2%
+21.2%
6 Month
+18.3%
+18.3%
1 Year
-0.1%
-0.1%

More News

Read More
Expert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 Analysts
Via Benzinga
Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Where ANI Pharmaceuticals Stands With Analysts
Via Benzinga
A Peek at ANI Pharmaceuticals's Future Earnings
Via Benzinga
Critical Insights From ANI Pharmaceuticals Analyst Ratings: What You Need To Know
Via Benzinga
1 Growth Stock to Target This Week and 2 to Avoid
Via StockStory
Exposures COVID-19
Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Why Is ANI Pharmaceuticals (ANIP) Stock Soaring Today
Via StockStory
ANI Pharmaceuticals Expects Strong Start To 2025, On Back Of Cortrophin Gel And Generics, Lifts Annual Forecast
Via Benzinga
Peeling Back The Layers: Exploring ANI Pharmaceuticals Through Analyst Insights
Via Benzinga
In-Depth Examination Of 4 Analyst Recommendations For ANI Pharmaceuticals
Via Benzinga
Get insights into the top gainers and losers of Friday's pre-market session.
Via Chartmill
ANI Pharmaceuticals (NASDAQ:ANIP) Delivers Impressive Q4, Stock Soars
Via StockStory
Earnings Scheduled For February 28, 2025
Via Benzinga
Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Unpacking Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) In The Context Of Other Generic Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
ANI Pharmaceuticals (NASDAQ:ANIP): Strongest Q3 Results from the Generic Pharmaceuticals Group
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Via Benzinga
ANI Pharmaceuticals Shifts Focus From Generics To High-Margin Brand Assets, Analyst Sees Strong Potential
Via Benzinga
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
Via Benzinga
ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger
From ANI Pharmaceuticals, Inc. and Alimera Sciences, Inc.
Via Business Wire

Frequently Asked Questions

Is ANI Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, ANI Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does ANI Pharmaceuticals, Inc. - Common Stock trade on?
ANI Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ANI Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for ANI Pharmaceuticals, Inc. - Common Stock is ANIP on the Nasdaq Stock Market
What is the current price of ANI Pharmaceuticals, Inc. - Common Stock?
The current price of ANI Pharmaceuticals, Inc. - Common Stock is 67.19
When was ANI Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of ANI Pharmaceuticals, Inc. - Common Stock was at 04/04/25 11:53 AM ET
What is the market capitalization of ANI Pharmaceuticals, Inc. - Common Stock?
The market capitalization of ANI Pharmaceuticals, Inc. - Common Stock is 1.64B
How many shares of ANI Pharmaceuticals, Inc. - Common Stock are outstanding?
ANI Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.